Lymphoma, T-Cell, Cutaneous Clinical Trial
Official title:
Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac
The study purpose is to evaluate the clinical response to multidose administration of anti-Tac monoclonal antibody conjugated with 10 mCi 90Y in patients with Tac-expressing adult T-cell leukemia (ATL).
The study purpose is to evaluate the clinical response to multidose administration of anti-Tac monoclonal antibody conjugated with 10 mCi 90Y in patients with Tac-expressing adult T-cell leukemia (ATL). This study represents an extension of phase I trial (Clinical Project #90-C-0043, FDA IND #3469) which permitted the administration of 5 mCi, 10 mCi, and 15mCi 90Y-anti-Tac to patients with ATL. We propose to administer 90Y-anti-Tac (10 mCi doses) to patients with Tac-expressing ATL who are over 18 years of age and who fill the patient eligibility criteria. ;
Endpoint Classification: Safety Study, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03357224 -
PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)
|
Phase 2 | |
| Completed |
NCT02567656 -
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
|
Phase 1 | |
| Completed |
NCT00051012 -
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
|
Phase 4 | |
| Recruiting |
NCT03646422 -
AEDV Registry of Primary Cutaneous Lymphoma
|
||
| Terminated |
NCT03789864 -
Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides
|
N/A | |
| Active, not recruiting |
NCT04998331 -
A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin
|
||
| Active, not recruiting |
NCT02953301 -
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)
|
Phase 2 | |
| Completed |
NCT01433731 -
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
|
Phase 1 | |
| Completed |
NCT01486277 -
A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
|
Phase 2 | |
| Completed |
NCT05137847 -
A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
|
||
| Active, not recruiting |
NCT03902184 -
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT00896493 -
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT00211198 -
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
|
Phase 4 | |
| Terminated |
NCT03601819 -
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
|
Phase 1 | |
| Withdrawn |
NCT03742804 -
Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT02836886 -
VircapSeq Virus Detection in Sézary Syndrome
|
||
| Completed |
NCT00050999 -
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
|
Phase 4 | |
| Terminated |
NCT02323659 -
Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas
|
Phase 4 | |
| Recruiting |
NCT02840747 -
Tissue Repository: CTCL Collection Protocol
|
||
| Completed |
NCT03192202 -
AFM13 in Relapsed/Refractory Cutaneous Lymphomas
|
Phase 1/Phase 2 |